Literature DB >> 1647076

The fusion and hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus 3 are both required for fusion.

S N Ebata1, M J Côté, C Y Kang, K Dimock.   

Abstract

Recombinant vaccinia viruses, VF and VHN, expressing the fusion (F) and hemagglutinin-neuraminidase (HN) glycoproteins of human parainfluenza virus 3 (HPIV3) were constructed. Infection of HeLa T4 cells with VF and VHN led to the synthesis of glycoproteins, with the correct apparent molecular weights, that were recognized by monoclonal antibodies specific for HPIV3F and HN. The HN glycoprotein was present on the surface of cells infected with VHN and these cells demonstrated both hemadsorbing and neuraminidase activities. The F glycoprotein was present in cleaved and uncleaved forms and was also expressed on the surface of VF-infected cells. Fusion activity, however, as evidenced by syncytium formation and lysis of human erythrocytes, could only be demonstrated when HeLa T4 cells were coinfected with VF and VHN. Fusion events that are mediated by HPIV3, therefore, require both the F and HN glycoproteins.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647076     DOI: 10.1016/0042-6822(91)90162-5

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

1.  Biological activity of paramyxovirus fusion proteins: factors influencing formation of syncytia.

Authors:  C M Horvath; R G Paterson; M A Shaughnessy; R Wood; R A Lamb
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  Analysis of the fusion protein gene of the porcine rubulavirus LPMV: comparative analysis of paramyxovirus F proteins.

Authors:  M Berg; A C Bergvall; M Svenda; A Sundqvist; J Moreno-López; T Linné
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

3.  Transfection of Sendai virus F gene cDNA with mutations at its cleavage site and HN gene cDNA into COS cells induces cell fusion.

Authors:  H Taira; T Sato; H Segawa; M Chiba; T Katsumata; K Iwasaki
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

4.  Identification of an amino acid that defines the fusogenicity of mumps virus.

Authors:  K Tanabayashi; K Takeuchi; K Okazaki; M Hishiyama; A Yamada
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

5.  Quantitative measurement of paramyxovirus fusion: differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 3 or Newcastle disease virus.

Authors:  S Bagai; R A Lamb
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  gp120-independent fusion mediated by the human immunodeficiency virus type 1 gp41 envelope glycoprotein: a reassessment.

Authors:  L Marcon; J Sodroski
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  Fusion regulation proteins on the cell surface: isolation and characterization of monoclonal antibodies which enhance giant polykaryocyte formation in Newcastle disease virus-infected cell lines of human origin.

Authors:  Y Ito; H Komada; S Kusagawa; M Tsurudome; H Matsumura; M Kawano; H Ohta; M Nishio
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

8.  Single event recording shows that docking onto receptor alters the kinetics of membrane fusion mediated by influenza hemagglutinin.

Authors:  W D Niles; F S Cohen
Journal:  Biophys J       Date:  1993-07       Impact factor: 4.033

9.  GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein.

Authors:  Dharmaraj Samuel; Weimei Xing; Anita Niedziela-Majka; Jinny S Wong; Magdeleine Hung; Katherine M Brendza; Michel Perron; Robert Jordan; David Sperandio; Xiaohong Liu; Richard Mackman; Roman Sakowicz
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

10.  Fusion mutants of Newcastle disease virus selected with monoclonal antibodies to the hemagglutinin-neuraminidase.

Authors:  R M Iorio; R L Glickman
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.